Vicore Pharma increases its holding in I-Tech AB

Vicore Pharma Holding (publ) (ticker:VICO) has increased its holding in I-Tech through a share issue.

Vicore Pharma Holding’s holding I-Tech AB has finalized a share issue directed to its current shareholders comprising a total of 10.4 million SEK. Vicore Pharma contributed with 2.5 million SEK and now holds 21% of the shares in I-Tech AB.

I-Tech has recently engaged Hempel, an international marine paint company as a second global customer, and the future development of the company looks positive.

“There is a strong potential with I-Tech and its antifouling technology Selektope®. The share issue conditions were beneficial and we view this as a favourable investment for Vicore Pharma Holding” says Per Jansson, CEO

For further information, please contact
Per Jansson, CEO
M: +46 709 17 47 46 or e-mail: 
per.jansson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14:10 CET on December 22, 2017

About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see  www.vicorepharma.com

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links